摘要
前列腺癌是男性生殖系统常见的恶性肿瘤,当发展为去势抵抗性前列腺癌后,其临床治疗变得更为困难。近年来,随着对去势抵抗性前列腺癌的深入研究,一大批具有新型作用机制的药物相继问世。对具有不同作用机制的新型去势抵抗性前列腺癌治疗药物,包括细胞色素P450酶17抑制剂、雄激素受体拮抗剂、肿瘤疫苗、抑制Bcl-2表达的药物、热休克蛋白抑制剂及血管生成抑制剂进行综述。
Prostate cancer is one kind of common malignant tumors in male genitourinary system. Its clinical treatment becomes more difficult when this disease progresses to castration-resistant prostate cancer （CRPC）. With the further research on CRPC, more and more drugs with novel action mechanisms have entered the market or put into the clinical research in recent years. The new drugs for the treatment of CRPC, including inhibitors of CYP17, antagonists of androgen receptor, tumor vaccine, inhibitors of Bcl-2 expression, inhibitors of heat shock proteins （HSPs） and angiogenesis inhibitors, were summarized in this paper.
出处
《药学进展》
CAS
2013年第5期193-199,共7页
Progress in Pharmaceutical Sciences
基金
"十二五"重大新药创制项目(No.2011ZX09102-001-05)
科技基础设施建设计划-江苏省创新平台提升项目(No.BM2012012)
关键词
去势抵抗性前列腺癌
作用机制
雄激素受体
新药研发
castration-resistant prostate cancer
action mechanism
androgen receptor
new＇ drug develo-pment
